Navigation Links
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Date:2/6/2009

idenix.com.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

Idenix Pharmaceuticals Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipate," "could," "may," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in HIV, or any potential pipeline candidates for the treatment of HIV, including any expressed or implied statement regarding the efficacy and safety of IDX899 and any future clinical trials involving IDX899. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre-clinical studies and/or clinical trials evaluating its product candidates, including IDX899; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; changes in the company's business pl
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...-NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecompan...surgicaltreatmentsforthespine,announcedtodaythatit...5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocuson...sproductsandwillincludecommentsfrommanagementfollo...ersare1-877-407-4018fordomesticcallersand1-201-689...
(Date:11/25/2009)...er.comannouncesthatanewmarketresearchreportisavail...rends ,, http://www.reportlinker.com/p016422...spreadavailabilityofgenericdrugs,emergenceofpainma...tedthepaceofgrowthinthepainmanagementmarket.Health...edemandforservices,drugsanddevices.Themarketisprim...
(Date:11/25/2009)...vember25/PRNewswire/--,iThembaPharmaceuticals,serv...yhavesignedacollaborativeagreementtojointlymarketb...mputationalchemistryandleaddiscoveryexpertise,will...cinaland,syntheticchemistrysupporttoprojectsidenti...baPharmaceuticalsandPyxisDiscovery,alsoannouncedto...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Atlanta Sports Medicine Doctor Spero Karas Wins 26apos 3BAtlanta 26apos 3Bs Top Doctors 26apos 3B Honor Again 52488 1Atlanta Sports Medicine Doctor Spero Karas Wins 26apos 3BAtlanta 26apos 3Bs Top Doctors 26apos 3B Honor Again 52488 2Atlanta Sports Medicine Doctor Spero Karas Wins 26apos 3BAtlanta 26apos 3Bs Top Doctors 26apos 3B Honor Again 52488 3Cell Therapeutics Inc Announces Pricing of Public Offering of Common Stock and Warrants 13161 1Cell Therapeutics Inc Announces Pricing of Public Offering of Common Stock and Warrants 13161 2Cell Therapeutics Inc Announces Pricing of Public Offering of Common Stock and Warrants 13161 3Michigan State Medical Society Weighs in on Proposed Federal Health Care Reform Legislation 52481 1Michigan State Medical Society Weighs in on Proposed Federal Health Care Reform Legislation 52481 2
...Versant Ventures Leads Investment in Lutonix to Fu...utonix Inc., today announced the,close of a $20 mi...by,Dennis Wahr, M.D. and Lixiao Wang PhD, Lutonix ...ment and commercialization of drug coated balloon,...ntion of coronary and,peripheral artery stenosis c...
...WHITE PLAINS, N.Y., Oct. 27 A doctor who is,inter...al nutrition, and,specifically for research on DHA... Dimes Agnes Higgins Award for outstanding achieve...usan E. Carlson, Ph.D., was among the first to rep...DHA (dietary docosahexaenoic acid) levels,than for...
Other Medicine Technology:Lutonix Inc. Announces $20 Million Series B Financing 2Lutonix Inc. Announces $20 Million Series B Financing 3March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition 2
(Date:11/25/2009)...E,Calif.,Nov.25/PRNewswire-FirstCall/-- OnyxPharm...ecompanywillhosttwoinvestoreventsinDecember: ,,.../10:00a.m.ET ,, Principalinvestigatorswilldis...sedand/orrefractorymultiplemyeloma,asfeaturedatthe...ndExpositioninNewOrleans,LA.Theteleconferencewillb...
(Date:11/25/2009)...,Calif.,Nov.25/PRNewswire/--Thanksgivingmealswillb...egreaterLongBeachareathankstoFaithInAction/Volunte...ome(IAH),adivisionofSCANHealthPlan.Formorethan17ye...erstodeliverwarmThanksgivingmealstoseniorsinneedin...elesandsurroundingcities. ,, "Ourwarmholidaymea...
(Date:11/25/2009)...SCO,Nov.25/PRNewswire/--TheBayAreaAirQualityManage...are the Air Alert forThursday,November2...nyothersolidfuel,bothindoorsandoutdoors. ,, "Co...tomorrow,"saidJackBroadbent,executiveofficeroftheA...ehealthoftheirneighborsandfellowcommunitymembersth...
(Date:11/25/2009)...e found evidence of a statistically significant su...nts whose estrogen receptor (ER)-positive tumors h...serine-118 (ER-alpha S118-P), according to a brief... Journal of the National Cancer Institute . , A...t to tamoxifen. Preclinical studies have shown tha...
(Date:11/25/2009)...up period was too short to draw definite conclusio... (HealthDay News) -- In diabetic patients with blo...ference in outcomes at one year whether patients u..., British researchers report. , Bypass surgery ...nts with coronary artery disease. However, less in...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
... ISO 9001:2000 certification recognizes ISI,s CA a...submission processes excellence, - Certifications ... China, - ISI plans to seek certification for Eur...ding software and services to streamline the drug,...
...edical University of South Carolina Becomes One of...ld,s First Adaptive CT Scanner, MALVERN, Pa., Jun...www.siemens.com/healthcare ) has received FDA 510(...ston is one of the first facilities to install the...
...ive Dad the Gift of Good Sleep and Good Health thi...e Majority of These Men - Suffer from ...AS, June 9 Families sick and tired of Dad,s rauco...d,exclusively to the evaluation and treatment of s...
... CINCINNATI Research led by scientists at Cincin...ed new clues into what causes different types of a...own as mixed lineage leukemias (MLL) and how the d... cells can be altered to form a particular type, o...
...ew Jersey-Based physician office is proof that sma... for eRx adoption, DALLAS, June 9 /PRNewswire/ -... leader in hosted services for email encryption an...nator Max Baucus (D- MT), chairman of the Senate F...
... The University of Kentucky is conducting a first...icle (ATV) safety, particularly in children. UK tr...estigator of a comprehensive multi-year investigat...Biomedical Research Facility on the UK campus. , ...
Other Medicine News:Health News:ISI Receives New ISO 9001:2000 Certifications in California and New Jersey 2Health News:ISI Receives New ISO 9001:2000 Certifications in California and New Jersey 3Health News:Siemens SOMATOM Definition AS Receives FDA Clearance 2Health News:Siemens SOMATOM Definition AS Receives FDA Clearance 3Health News:Siemens SOMATOM Definition AS Receives FDA Clearance 4Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 3Health News:Microenvironment a main driver of aggressive multi-lineage leukemia disease type 2Health News:Microenvironment a main driver of aggressive multi-lineage leukemia disease type 3Health News:Microenvironment a main driver of aggressive multi-lineage leukemia disease type 4Health News:Video: Zix Corporation Issues Statement Supporting Bipartisan Push for Medicare e-Prescribing Requirement 2Health News:Video: Zix Corporation Issues Statement Supporting Bipartisan Push for Medicare e-Prescribing Requirement 3Health News:Video: Zix Corporation Issues Statement Supporting Bipartisan Push for Medicare e-Prescribing Requirement 4Health News:Video: Zix Corporation Issues Statement Supporting Bipartisan Push for Medicare e-Prescribing Requirement 5Health News:ATV study to improve fit, safety among kids 2
Carcinoembryonic Antigen (CEA) - Rapid Test
...174 25-Hydroxyvitamin D Assay is for use only on t...chols Advantage® 25-Hydroxyvitamin D Assay is ...,hydroxyvitamin D (25-OH-D) and other hydroxylated... used as an aid in the assessment of vitamin D suf...
Roche/STAGO STA Compact
CoaguChek® Pro/DM
Medicine Products: